Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Depreciation & Amortization (CF) (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $15817.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 166.82% year-over-year to $15817.0, compared with a TTM value of $59866.0 through Oct 2025, up 156.81%, and an annual FY2025 reading of $59866.0, up 156.81% over the prior year.
  • Depreciation & Amortization (CF) was $15817.0 for Q4 2025 at Pharma-Bio Serv, roughly flat from $15744.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $21424.0 in Q1 2021 and bottomed at $4589.0 in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $12754.9, with a median of $13064.5 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 59.75% in 2024, then skyrocketed 243.08% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $14290.0 in 2021, then decreased by 10.43% to $12800.0 in 2022, then plummeted by 42.25% to $7392.0 in 2023, then decreased by 19.81% to $5928.0 in 2024, then surged by 166.82% to $15817.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for PBSV at $15817.0 in Q4 2025, $15744.0 in Q3 2025, and $18866.0 in Q2 2025.